Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 39.6× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GSG | IDXX | |
|---|---|---|
Market Cap | $1.02B | $40.43B |
Volume | 1,256,221 | 692,164 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $766.68 |
52-Week Low | $22.45 | $504.70 |
Typical Hold Time | 40 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
